Trials / Completed
CompletedNCT00870805
Ultrabrief Pulsewidth Electroconvulsive Therapy (ECT)
A Controlled Study of Ultrabrief Pulsewidth ECT (Electroconvulsive Therapy)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- The University of New South Wales · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Electroconvulsive Therapy (ECT) remains essential to contemporary psychiatric practice and is one of the safest and most effective treatments available for depression. Despite modern advances in pharmacotherapy, about 15-20 per cent of all hospitalised patients receive treatment with ECT. Its use, however, is limited by concerns over associated cognitive side effects. Recent research has suggested that using an ultrabrief pulsewidth with ECT may greatly reduce cognitive side effects, while maintaining efficacy (Sackeim et al 2008). Preliminary results were positive for unilateral ECT, however, suggest that for bilateral ECT, dosing may need to be adjusted to preserve efficacy while reducing side effects. This study will examine the relative cognitive side effects and efficacy of right unilateral and bilateral ECT given with a standard pulsewidth or an ultrabrief pulsewidth. Some participants will also receive an MRI scan before and after ECT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | bilateral ultrabrief ECT | Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms) |
| PROCEDURE | bilateral standard ECT | Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms) |
| PROCEDURE | right-unilateral ultrabrief ECT | Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms) |
| PROCEDURE | right-unilateral standard ECT | Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms) |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2009-03-27
- Last updated
- 2013-02-27
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00870805. Inclusion in this directory is not an endorsement.